 Celsion Corporation NASDAQ: CLSN has announced a poster highlighting its ongoing Phase 12 OVATION 2 Study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting on Womens Cancer. GEN-1 is a DNA-mediated interleukin-12 IL-12 immunotherapy designed using TheraPlas, its proprietary, synthetic, non-viral nanoparticle delivery system platform. 